• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多次给予间充质干细胞对成骨不全症患儿的营养作用。

Trophic effects of multiple administration of mesenchymal stem cells in children with osteogenesis imperfecta.

机构信息

Department of Paediatric Orthopaedics, Christian Medical College, Vellore, Tamil Nadu, India.

Center for Stem Cell Research, a unit of inStem Bengaluru, Christian Medical College, Vellore, Tamil Nadu, India.

出版信息

Clin Transl Med. 2021 Apr;11(4):e385. doi: 10.1002/ctm2.385.

DOI:10.1002/ctm2.385
PMID:33931966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8019582/
Abstract

The safety of mesenchymal stem cell therapy for osteogenesis imperfecta has been demonstrated previously. However, it is unknown how the trophic effects are mediated by stem cells. In the present commentary, we bring to the attention of readers the recent report by Infante et al in the journal of clinical and translational medicine. The TERCELOI clinical trial presented the possible paracrine effect of transplanted MSCs in vitro and in vivo using proteomics and transcriptomic analysis. This novel finding adds new knowledge in the field of regenerative medicine. However, the scarcity of solid evidence in growth warrants a more thorough discussion.

摘要

先前已经证明间充质干细胞治疗成骨不全症具有安全性。然而,干细胞通过何种方式发挥营养作用尚不清楚。在本期评论中,我们提请读者注意 Infante 等人在《临床与转化医学杂志》上发表的最新报告。TERCELOI 临床试验使用蛋白质组学和转录组学分析,提出了移植的间充质干细胞在体外和体内的旁分泌作用的可能性。这一新颖的发现为再生医学领域增添了新知识。然而,在生长方面缺乏确凿证据,需要进行更深入的讨论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8019582/b9074a5a87dd/CTM2-11-e385-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8019582/1d9884108728/CTM2-11-e385-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8019582/b9074a5a87dd/CTM2-11-e385-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8019582/1d9884108728/CTM2-11-e385-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8019582/b9074a5a87dd/CTM2-11-e385-g001.jpg

相似文献

1
Trophic effects of multiple administration of mesenchymal stem cells in children with osteogenesis imperfecta.多次给予间充质干细胞对成骨不全症患儿的营养作用。
Clin Transl Med. 2021 Apr;11(4):e385. doi: 10.1002/ctm2.385.
2
Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial.重复输注间充质干细胞可改善小儿成骨不全症,引发促成骨旁分泌反应:TERCELOI 临床试验。
Clin Transl Med. 2021 Jan;11(1):e265. doi: 10.1002/ctm2.265.
3
Osteogenesis imperfecta, rehabilitation medicine, fundamental research and mesenchymal stem cells.成骨不全、康复医学、基础研究与间充质干细胞
Connect Tissue Res. 1995;31(4):S9-14. doi: 10.3109/03008209509116826.
4
Gene targeting in stem cells from individuals with osteogenesis imperfecta.对成骨不全症患者干细胞进行基因靶向操作。
Science. 2004 Feb 20;303(5661):1198-201. doi: 10.1126/science.1088757.
5
Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience.成骨不全症胎儿间充质干细胞的产前和产后移植:两中心经验。
Stem Cells Transl Med. 2014 Feb;3(2):255-64. doi: 10.5966/sctm.2013-0090. Epub 2013 Dec 16.
6
Extracellular vesicles released from mesenchymal stromal cells stimulate bone growth in osteogenesis imperfecta.间质基质细胞释放的细胞外囊泡可刺激成骨不全症中的骨生长。
Cytotherapy. 2018 Jan;20(1):62-73. doi: 10.1016/j.jcyt.2017.09.012. Epub 2017 Oct 26.
7
Stakeholder views and attitudes towards prenatal and postnatal transplantation of fetal mesenchymal stem cells to treat Osteogenesis Imperfecta.利益相关者对产前和产后移植胎儿间充质干细胞治疗成骨不全症的看法和态度。
Eur J Hum Genet. 2019 Aug;27(8):1244-1253. doi: 10.1038/s41431-019-0387-4. Epub 2019 Mar 27.
8
Mesenchymal Stem Cell Therapy for Osteogenesis Imperfecta.间充质干细胞治疗成骨不全症。
Clin Obstet Gynecol. 2021 Dec 1;64(4):898-903. doi: 10.1097/GRF.0000000000000656.
9
Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms.移植的骨髓单核细胞和间充质干细胞通过不同的机制为成骨不全症患儿带来临床获益。
Blood. 2012 Aug 30;120(9):1933-41. doi: 10.1182/blood-2011-12-400085. Epub 2012 Jul 24.
10
Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta.干细胞疗法治疗成骨不全症。
Curr Osteoporos Rep. 2020 Aug;18(4):337-343. doi: 10.1007/s11914-020-00594-3.

引用本文的文献

1
Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies.间充质干细胞在治疗人类疾病中的应用:分子机制与临床研究
Signal Transduct Target Ther. 2025 Aug 22;10(1):262. doi: 10.1038/s41392-025-02313-9.
2
Evaluation of safety and efficacy of multiple intravenous and intraosseous doses of foetal liver-derived mesenchymal stem cells in children with severe osteogenesis imperfecta : the BOOST2B clinical trial protocol.多次静脉注射和骨内注射胎儿肝脏来源间充质干细胞治疗重度成骨不全患儿的安全性和有效性评估:BOOST2B临床试验方案
Bone Jt Open. 2025 Mar 24;6(3):361-372. doi: 10.1302/2633-1462.63.BJO-2024-0115.R1.
3

本文引用的文献

1
Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial.重复输注间充质干细胞可改善小儿成骨不全症,引发促成骨旁分泌反应:TERCELOI 临床试验。
Clin Transl Med. 2021 Jan;11(1):e265. doi: 10.1002/ctm2.265.
2
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study.iPSC 来源间充质基质细胞在急性激素耐药移植物抗宿主病中的生产、安全性和疗效:I 期、多中心、开放标签、剂量递增研究。
Nat Med. 2020 Nov;26(11):1720-1725. doi: 10.1038/s41591-020-1050-x. Epub 2020 Sep 14.
3
Comprehensive Review of Osteogenesis Imperfecta: Current Treatments and Future Innovations.
成骨不全症综述:当前治疗方法与未来创新
Hum Gene Ther. 2025 Mar;36(5-6):597-617. doi: 10.1089/hum.2024.191. Epub 2025 Feb 11.
4
The Role of Mitochondrial Homeostasis in Mesenchymal Stem Cell Therapy-Potential Implications in the Treatment of Osteogenesis Imperfecta.线粒体稳态在间充质干细胞治疗中的作用——对成骨不全症治疗的潜在影响
Pharmaceuticals (Basel). 2024 Sep 29;17(10):1297. doi: 10.3390/ph17101297.
5
Emerging Landscape of Osteogenesis Imperfecta Pathogenesis and Therapeutic Approaches.成骨不全症发病机制与治疗方法的新进展
ACS Pharmacol Transl Sci. 2024 Jan 2;7(1):72-96. doi: 10.1021/acsptsci.3c00324. eCollection 2024 Jan 12.
6
Mesenchymal stem cells in the treatment of osteogenesis imperfecta.间充质干细胞在成骨不全治疗中的应用
Cell Regen. 2023 Feb 2;12(1):7. doi: 10.1186/s13619-022-00146-3.
Mesenchymal Stem Cells Beyond Regenerative Medicine.
再生医学之外的间充质干细胞
Front Cell Dev Biol. 2020 Feb 18;8:72. doi: 10.3389/fcell.2020.00072. eCollection 2020.
4
Immunomodulatory Effects of MSCs in Bone Healing.间充质干细胞在骨愈合中的免疫调节作用。
Int J Mol Sci. 2019 Nov 2;20(21):5467. doi: 10.3390/ijms20215467.
5
Metabolism in Human Mesenchymal Stromal Cells: A Missing Link Between hMSC Biomanufacturing and Therapy?人骨髓间充质干细胞的代谢:hMSC 生物制造与治疗之间的缺失环节?
Front Immunol. 2019 May 8;10:977. doi: 10.3389/fimmu.2019.00977. eCollection 2019.
6
Gender-independent efficacy of mesenchymal stem cell therapy in sex hormone-deficient bone loss via immunosuppression and resident stem cell recovery.间充质干细胞通过免疫抑制和驻留干细胞恢复治疗性激素缺乏性骨丢失的性别无关疗效。
Exp Mol Med. 2018 Dec 17;50(12):1-14. doi: 10.1038/s12276-018-0192-0.
7
Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience.成骨不全症胎儿间充质干细胞的产前和产后移植:两中心经验。
Stem Cells Transl Med. 2014 Feb;3(2):255-64. doi: 10.5966/sctm.2013-0090. Epub 2013 Dec 16.
8
[Reproducibility and accuracy in the morphometric and mechanical quantification of trabecular bone from 3 Tesla magnetic resonance images].[3特斯拉磁共振图像小梁骨形态计量学和力学定量分析的可重复性和准确性]
Radiologia. 2014 Jan-Feb;56(1):27-34. doi: 10.1016/j.rx.2013.06.001. Epub 2013 Oct 2.
9
Assessment of 2D and 3D fractal dimension measurements of trabecular bone from high-spatial resolution magnetic resonance images at 3 T.3T 高空间分辨率磁共振成像的小梁骨 2D 和 3D 分形维数测量评估。
Med Phys. 2010 Sep;37(9):4930-7. doi: 10.1118/1.3481509.
10
The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy.脑瘫或肌肉营养不良儿童和青少年远端股骨骨折与 DXA 测量骨密度的关系。
J Bone Miner Res. 2010 Mar;25(3):520-6. doi: 10.1359/jbmr.091007.